Article
Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection.
Current medical science - 1 Jun 2021
Ahmed Manar, Mansey Azza E, Wahsh Engy A, Gomaa Ahmed A, Rabea Hoda M
Abstract excerpt
Hepatitis C virus genotype 4 (HCV-GT4) is a risk factor for cirrhosis, hepatocellular carcinoma and liver failure. A combination of three new direct-acting antivirals ombitasvir, paritaprevir, and ritonavir has been recommended for treatment of HCV-GT4 infection. The current study was aimed to assess the efficacy and safety of this combination plus ribavirin in non-cirrhotic, treatment-naïve and -experienced...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.